Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter randomized phase III trial comparing Avelumab vs genomic driven chemotherapy and genomic driven chemotherapy vs standard chemotherapy according to investigator's choice in elderly untreated Non-small cell lung cancer

Next Previous
Trial Profile

A multicenter randomized phase III trial comparing Avelumab vs genomic driven chemotherapy and genomic driven chemotherapy vs standard chemotherapy according to investigator's choice in elderly untreated Non-small cell lung cancer

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Carboplatin; Docetaxel; Gemcitabine; Pemetrexed; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms EPIC

Most Recent Events

  • 01 Oct 2019 Enrollment completion is expected by the end of 2022, according to the Trial design presented at the 44th European Society for Medical Oncology Congress.
  • 01 Oct 2019 Trial design presented at the 44th European Society for Medical Oncology Congress.
  • 01 Oct 2019 On June 2018 the protocol was amended with the introduction of a new study arm (Avelumab), aiming to clarify the best strategy in elderly untreated NSCLC patients, according to the Trial design presented at the 44th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top